순환종양세포(CTCs) 및 암 줄기세포(CSCs) : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
상품코드:1872189
리서치사:QYResearch
발행일:2025년 10월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 순환종양세포(CTCs) 및 암 줄기세포(CSCs) 시장 규모는 2024년에 211억 3,200만 달러로 추정되며, 2025-2031년의 예측 기간 중 CAGR 21.4%로 성장하며, 2031년까지 806억 7,500만 달러로 확대할 것으로 예측됩니다.
순환종양세포(CTCs)는 원발성 종양에서 떨어져 나와 혈류를 타고 이동하는 종양세포로, 원발성 종양에서 다른 부위로 퍼져나가 암 전이를 일으킵니다. 이 세포는 암 환자의 말초혈액에 존재하며, CTC의 검출은 전이 과정을 판단하는 데 도움이 됩니다. 다른 혈액세포와 달리 CTCs의 혈중 농도는 극히 드물기 때문에 검출이 어렵습니다. 암 줄기세포(CSCs)는 정상 줄기세포의 고전적인 특성을 모두 갖춘 암세포입니다. 구체적으로는 자기복제 능력과 암 조직 내에 존재하는 모든 세포 유형을 생성하는 능력을 모두 가지고 있습니다.
순환종양세포(CTCs) 및 암줄기세포(CSCs) 시장은 암 연구, 진단 및 치료 개발에서 중요한 역할을 하면서 빠르게 성장하고 있습니다. 원발성 또는 전이성 종양에서 혈류로 유입되는 CTCs는 액체생검에 귀중한 정보를 제공하여 비침습적 암 감지, 실시간 모니터링 및 맞춤 치료를 가능하게 합니다. 한편, CSC는 자가 재생 능력을 가지고 종양의 진행, 전이, 치료 저항성을 촉진하는 종양 세포의 하위 포퓰레이션입니다. 이러한 세포 유형은 암 생물학에 대한 이해와 표적 치료법 개발에 필수적이며, 첨단 분리, 특성화 및 분석 기술에 대한 수요를 촉진하고 있습니다.
마이크로플루이딕스 기술, 면역 자기 분리, 단일 세포 분석과 같은 검출 및 농축 기술의 혁신은 이 시장의 주요 성장 요인입니다. 제약회사와 생명공학 기업은 신약개발, 내성 메커니즘 연구, 맞춤형 암 치료 접근법을 위해 CTC 및 CSC 분석을 점점 더 많이 활용하고 있습니다. 인공지능과 유전체 시퀀싱의 통합으로 이러한 플랫폼의 정확도와 예측 가치는 더욱 향상되고 있습니다. 정밀의료와 액체생검 용도의 부상으로 CTC와 CSC를 결합한 시장은 암 진단 및 치료 전략 개발의 기반이 될 것으로 기대되고 있습니다.
이 보고서는 세계의 순환종양세포(CTCs) 및 암 줄기세포(CSCs) 시장에 대해 총매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
순환종양세포(CTCs) 및 암 줄기세포(CSCs) 시장 규모, 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020-2031년의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적 분석과 정성적 분석을 통해 순환종양세포(CTCs) 및 암줄기세포(CSCs)에 대한 비즈니스/성장 전략을 수립하고, 시장 경쟁을 평가하고, 현재 시장에서의 포지셔닝을 분석하고, 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다. 의사결정을 도와드립니다.
시장 세분화
기업별
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
유형별 부문
CellSearch
기타
용도별 부문
유방암 진단과 치료
전립선암 진단과 치료
대장암 진단과 치료
폐암 진단과 치료
기타 암 진단과 치료
지역별
북미
미국
캐나다
아시아태평양
중국
일본
한국
동남아시아
인도
호주
기타 아시아태평양
유럽
독일
프랑스
영국
이탈리아
네덜란드
북유럽 국가
기타 유럽
라틴아메리카
멕시코
브라질
기타 라틴아메리카
중동 및 아프리카
튀르키예
사우디아라비아
아랍에미리트
기타 중동 및 아프리카
KSA
영문 목차
영문목차
The global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) was estimated to be worth US$ 21132 million in 2024 and is forecast to a readjusted size of US$ 80675 million by 2031 with a CAGR of 21.4% during the forecast period 2025-2031.
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect. Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The market for circulating tumor cells (CTCs) and cancer stem cells (CSCs) is expanding rapidly due to their critical role in cancer research, diagnosis, and therapy development. CTCs, which enter the bloodstream from primary or metastatic tumors, provide valuable insights for liquid biopsy, enabling non-invasive cancer detection, real-time monitoring, and treatment personalization. CSCs, on the other hand, are a subpopulation of tumor cells with the ability to self-renew and drive tumor progression, metastasis, and therapy resistance. Together, these cell types are essential for understanding cancer biology and developing targeted therapies, fueling demand for advanced isolation, characterization, and analysis technologies.
Innovation in detection and enrichment technologies-such as microfluidics, immunomagnetic separation, and single-cell analysis-is a major growth driver in this market. Pharmaceutical and biotech companies are increasingly leveraging CTC and CSC analysis for drug discovery, resistance mechanism studies, and personalized oncology approaches. Integration of artificial intelligence and genomic sequencing is further enhancing the accuracy and predictive value of these platforms. With the rise of precision medicine and liquid biopsy applications, the combined CTC and CSC market is expected to become a cornerstone in oncology diagnostics and therapeutic strategy development.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by region & country, by Type, and by Application.
The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
Market Segmentation
By Company
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Segment by Type
CellSearch
Others
Segment by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Introduction
1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Forecast (2020-2031)
1.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trends & Drivers
1.3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
1.3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers & Opportunity
1.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
1.3.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Ranking (2024)
2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Company (2020-2025)
2.3 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Offered
2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
2.6 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Analysis
2.6.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CellSearch
3.1.2 Others
3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type
3.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (2020-2031)
3.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Breast Cancer Diagnosis and Treatment
4.1.2 Prostate Cancer Diagnosis and Treatment
4.1.3 Colorectal Cancer Diagnosis and Treatment
4.1.4 Lung Cancer Diagnosis and Treatment
4.1.5 Other Cancers Diagnosis and Treatment
4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application
4.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (2020-2031)
4.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region
5.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2020-2025)
5.1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2026-2031)
5.1.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
5.2.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
5.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
5.4.2 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
5.5.2 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
5.6.2 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.3 United States
6.3.1 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.3.2 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.4.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.5.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
6.5.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.6.2 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.7.2 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.8.2 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
6.9.2 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
6.9.3 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Janssen
7.1.1 Janssen Profile
7.1.2 Janssen Main Business
7.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
7.1.5 Janssen Recent Developments
7.2 Qiagen
7.2.1 Qiagen Profile
7.2.2 Qiagen Main Business
7.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
7.2.5 Qiagen Recent Developments
7.3 Advanced Cell Diagnostics
7.3.1 Advanced Cell Diagnostics Profile
7.3.2 Advanced Cell Diagnostics Main Business
7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
